[
  {
    "ts": null,
    "headline": "Regeneron Announces Investor Conference Presentations",
    "summary": "TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on Tuesday, November 19, 2024 • Piper Sandler 36th Annual Healthcare Conference at 9:30 a.m. ET on Thursday, December 5, 2024 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replay",
    "url": "https://finnhub.io/api/news?id=1fd3b2cacc0f7b4d898bac270cba9d9eb9fedd1ea3d3b50b6a38f8e2fcc4734b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731359100,
      "headline": "Regeneron Announces Investor Conference Presentations",
      "id": 131294806,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "TARRYTOWN, N.Y., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • Jefferies London Healthcare Conference at 11:00 a.m. BST (6:00 a.m. ET) on Tuesday, November 19, 2024 • Piper Sandler 36th Annual Healthcare Conference at 9:30 a.m. ET on Thursday, December 5, 2024 The sessions may be accessed from the \"Investors & Media\" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replay",
      "url": "https://finnhub.io/api/news?id=1fd3b2cacc0f7b4d898bac270cba9d9eb9fedd1ea3d3b50b6a38f8e2fcc4734b"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=f4ec31512ce086755a2e2160fd659cebbbaca5f3c9886d101535a777c4c88039",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731343440,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 131418670,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=f4ec31512ce086755a2e2160fd659cebbbaca5f3c9886d101535a777c4c88039"
    }
  },
  {
    "ts": null,
    "headline": "Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus",
    "summary": "Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the...",
    "url": "https://finnhub.io/api/news?id=63ee4af69c367107ff47cbf82813be0259afe783c9bfb08baa6b8e9880d58c44",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731313800,
      "headline": "Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus",
      "id": 131284392,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/958260280/image_958260280.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Intellia Therapeutics' NTLA-2002 Phase II results last month were underwhelming, however, management reassured investors on the Q3 earnings call setting the...",
      "url": "https://finnhub.io/api/news?id=63ee4af69c367107ff47cbf82813be0259afe783c9bfb08baa6b8e9880d58c44"
    }
  }
]